Thousands of men with prostate cancer could be safely spared chemotherapy, after research found some were not helped by it.A study of more than 2,000 men with advanced prostate cancer showed that on average, docetaxel chemotherapy improved five-year survival rates.It was more effective in men with many metastases – meaning the cancer had spread – when diagnosed. But men with fewer metastases whose cancer was caught earlier did not benefit at all.
Load More
Load More
